Doximity plummets on FY26, FQ4 revenue guidance

 

• Although Doximity's (DOCS) fiscal 2026 Q3 results beat on both sides, shares are down ~33% in after-hours trading as revenue guidance ranges for Q4 and FY 26 are below consensus.
• The digital platform for doctors company sees FQ4 revenue of $143M-$144M. Consensus is $150.53M. For FY26, it is projecting revenue of $642.5M-$643.5M. Consensus is $645.36M.
• Doximity also said its board has authorized a $500M stock buyback program.
• In FQ3 (ended Dec. 31, 2025), Doximity's non-GAAP EPS of $0.46 compares to $0.45 in the year-ago period. Net income in the quarter declined to ~$61.6M from ~$75.2M in FY25 Q3 due to a ~27% year-over-year increase in marketing expenses. That negated the ~10% YoY increase in revenue. 
• Doximity ended the quarter with cash, cash equivalents, and marketable securities of ~$735.1M compared to ~$915.7M on March 31, 2025. 

https://www.msn.com/en-us/money/companies/doximity-plummets-on-fy26-fq4-revenue-guidance/ar-AA1VLCq4